posted
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs' May 10, 2006 10:30:00 AM PALO ALTO, CALIFORNIA -- (MARKET WIRE) -- 05/10/06 -- Human BioSystems (OTCBB: HBSC), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts: Human BioSystems Harry Masuda CEO (650) 323-0943 hmasuda*humanbiosystems.com
Yes International Rich Kaiser Investor Relations (800) 631-8127 rich*yesinternational.com
Posts: 2049 | From: Jax,FL,USA | Registered: Nov 2003
| IP: Logged |
posted
Breaking News: Human BioSystems Completes Platelet Testing at Second Independent Laboratory Human BioSystems ("HBS") (OTCBB: HBSC), a developer of preservation platforms for organs and other biomaterials, specializing in the development of proprietary above zero ("HBS-AZ") and below zero ("HBS-BZ") organ and tissue preservation systems and methods for preserving blood platelets, announced today that it has completed blood platelet testing at a second independent laboratory.
"Under an agreement signed in June 2005, the laboratory has assisted HBS in testing our methods and protocols for extending the shelf life of blood platelets," said Dr. David Winter, President of Human BioSystems.
This second in-vitro study involving the cold storage of human platelets started in January of 2006 was recently completed. Ten subjects were involved and the results were consistent with those of a previous independent study. Both of these studies utilized technology covered by a patent application for which HBS has received a Notice of Allowability.
HBS is now preparing to submit an application to the FDA within the next few months in order to obtain a license for conducting human infusion studies. Favorable test results should position HBS for strategic partnering and licensing of its technology.
Blood platelets are the clotting component of blood and are collected from donors and infused into cancer patients who have undergone chemotherapy and/or radiation treatments. Such treatments inhibit the production of platelets for a period of time, possibly resulting in bleeding without regular platelet infusion.
"Currently, platelets have an FDA mandated five day shelf life. It is our goal to extend the shelf life by utilizing the proprietary HBS solution and process to preserve platelets at refrigerated temperatures for at least seven or more days," according to Dr. Winter.
"We believe that when our technology is brought to market it should drastically reduce the outdating of platelets, allowing blood centers to significantly reduce their costs without changing their existing basic procedures. The total worldwide loss due to outdating is estimated by HBS to exceed one billion dollars at the hospital level based on 6 million transfusion units collected annually and an outdate percentage of 15%. Refrigeration should inhibit bacteria growth, resulting in a safer product," added Harry Masuda, CEO of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for human studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, issues with the patentability and/or protection of the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
Wow, looks very promising. I'm in. HBS is now preparing to submit an application to the FDA within the next few months in order to obtain a license for conducting human infusion studies. Favorable test results should position HBS for strategic partnering and licensing of its technology...
"We believe that when our technology is brought to market it should drastically reduce the outdating of platelets, allowing blood centers to significantly reduce their costs without changing their existing basic procedures. The total worldwide loss due to outdating is estimated by HBS to exceed one billion dollars at the hospital level based on 6 million transfusion units collected annually and an outdate percentage of 15%. Refrigeration should inhibit bacteria growth, resulting in a safer product," added Harry Masuda, CEO of Human BioSystems.
Posts: 191 | From: Ontario, Canada | Registered: Mar 2006
| IP: Logged |
posted
Got a few shares of this myself. Good to see some upswing going on this one...
Posts: 741 | From: North Carolina | Registered: Feb 2006
| IP: Logged |
posted
1,071,428 shares bought by insiders in August at .14/share code P. Code P is open market or private purchase, very bullish.
Posts: 79 | Registered: Aug 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
